Early prediction of pathologic response to neoadjuvant treatment of breast cancer: use of a cell-loss metric based on serum thymidine kinase 1 and tumour volume

Table 3 Pathologic outcome and cell-loss metric 48 h after the 2nd cycle of therapy

Statistics	pCR*	pT1	pT2 + pT3
n (%)	24 (23.1)	38 (36.5)	42 (40.4)
Mean (Std)**	0.22 (0.47)	0.08 (0.22)	0.05 (0.11)
Median (min;max)	0.06 (0.0;1.87)	0.02 (0;1.25)	0.01 (0.0;0.46)
Q1, Q3 (IQR)	0.02, 0.22 (0.21)	0.01, 0.04 (0.03)	0.004, 0.03 (0.03)

*) pCR denotes pathological complete response in the breast
**) Values are units (sTk1, ng x ml⁻¹ / tumor volume, cm³)
Descriptive statistics of the TK1-based cell-loss metric 48 h after the 2nd cycle of chemotherapy among 104 women grouped according to pathological status at surgery. The surgery was performed after six cycles of chemotherapy

ISSN: 1471-2407